Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Fiscal Implications of Newborn Screening in the Diagnosis of Severe Combined Immunodeficiency
Journal of Allergy and Clinical Immunology: In Practice, Volume 2, No. 6, Year 2014
Notification
URL copied to clipboard!
Description
In the United States, newborn screening (NBS) is currently recommended for identification of 31 debilitating and potentially fatal conditions. However, individual states determine which of the recommended conditions are screened. The addition of severe combined immunodeficiency (SCID) screening to the recommended NBS panel has been fully instituted by 18 states, with another 11 states piloting programs or planning to begin screening in 2014. Untreated, SCID is uniformly fatal by 2 years of age. Hematopoietic stem cell transplantation usually is curative, but the success rate depends on the age at which the procedure is performed. Short-term implementation costs may be a barrier to adding SCID to states' NBS panels. A retrospective economic analysis was performed to determine the cost-effectiveness of NBS for early (<3.5 months) versus late (≥3.5 months) treatment of children with SCID at 3 centers over 5 years. The mean total charges at these centers for late treatment were 4 times greater than early treatment ($1.43 million vs $365,785, respectively). Mean charges for intensive care treatments were >5 times higher ($350,252 vs $66,379), and operating room-anesthesia charges were approximately 4 times higher ($57,105 vs $15,885). The cost-effectiveness of early treatment for SCID provides a strong economic rationale for the addition of SCID screening to NBS programs of other states. © 2014 American Academy of Allergy, Asthma & Immunology.
Authors & Co-Authors
Jyonouchi, Soma C.
United States, Philadelphia
The Children's Hospital of Philadelphia
Kuo, Caroline Y.
United States, Los Angeles
University of California, Los Angeles
Garcia-Lloret, Maria Ines
United States, Los Angeles
University of California, Los Angeles
Dorsey, Morna J.
United States, Tampa
University of South Florida, Tampa
Sleasman, John William
United States, Tampa
University of South Florida, Tampa
Perez, Elena Elizabeth
United States, Tampa
University of South Florida, Tampa
Statistics
Citations: 27
Authors: 6
Affiliations: 4
Identifiers
Doi:
10.1016/j.jaip.2014.05.013
ISSN:
22132198
Research Areas
Maternal And Child Health
Study Design
Cohort Study